for 87 participants. Group differences at one year on the Home Situations and Aberrant Behavior Checklists were no longer significant. Data were not available for Vineland at one-year followup. 167 , 179-181 62 Table 10. Summary of outcomes of studies of interventions targeting conditions commonly associated with ASD Author, Year, Country Groups, N Enrollment/N Final Study Quality Age, Mean Years±SD IQ, Mean±SD Key Outcomes CBT Studies Storch et al. 2013 177 US G1: CBT, 24/22 G2: Usual care, 21/21 Quality: Good G1: 8.83±1.31 G2: 8.95 ± 1.40 NR • Significantly greater improvements in all primary outcomes for G1 compared with G2; effect sizes ranged from 0.84 to 1.06 • Pediatric Anxiety Rating Scale ratings were reduced by 29% for G1 vs. 9% for G2 (effect size=1.03, p<.01) • CGI-S improved from a mean 3.50 for G1 at baseline to 2.67 at followup compared with baseline mean of 4.00 and followup of 3.57 for usual care (effect size=1.06, p<.01) • On the blinded, clinician-rated Anxiety Disorders Interview Schedule, 38% (9/24) G1 participants vs. 5% (1/21) G2 participants achieved clinical remission of anxiety symptoms (effect size=1.37, p=.01) • At followup of G1 three months post-treatment, 11/15 maintained treatment response and 6/9 maintained remission (p=NS); scores on the CGI- S, Anxiety Disorders Interview Schedule, and Pediatric Anxiety Rating Scale did not change significantly from end of treatment Keehn et al. 2013 176 US G1: CBT, 12/12 G2: Wait list control, 10/10 Quality: Good G1: 11.65 ± 1.41 G2: 11.02±1.69 G1: 108.42±17.70 G2: 110.40 ± 17.39 • On blinded, clinician-rated Anxiety Disorders Interview Schedule, 58% of G1 no longer met criteria for primary anxiety diagnosis at followup; 100% of G2 still met criteria (p=.003) • Parent-reported Spence Children’s Anxiety Scale ratings improved over time for G1 compared with G2 (baseline means: G1=34.92, G2=32.20; at followup G1=20.08, 31.70, p=.02) • Co-morbid diagnoses decreased in G1 compared with G2 from baseline to followup (p<.001) • 4/11 treatment group participants with 2-month post-treatment followup data continued not to meet criteria for anxiety diagnosis • NNT=1.72 Reaven et al. 2012 173 US G1: CBT , 24/21 G2: Usual care, 26/26 Quality: Good G1: 125.75 months±21.47 G2: 125.00 months±20.45 G1: 107.08 ± 16.85 G2: 102.23±17.33 • Blinded clinician severity ratings significantly reduced from baseline for all anxiety diagnoses in G1 compared with G2; effect sizes ranged from medium to large • Significant reduction in overall number of anxiety disorders in G1 compared with G2 at followup; large effect size for reduction in generalized anxiety disorder diagnoses (effect size=0.85) but no significant between group differences in diagnostic status for other anxiety diagnoses • 50% of G1 and 8.7% of G2 had clinically meaningful improvement in anxiety symptoms on the CGI-S (effect size=1.03, p=.003) • At 6 month post-intervention followup for G1, parent and child SCARED scores suggested maintenance of reduction of anxiety symptoms 63 Table 10. Summary of outcomes of studies of interventions targeting conditions commonly associated with ASD (continued) Author, Year, Country Groups, N Enrollment/N Final Study Quality Age,